Podcast: Play in new window | Download
The Big Ones
Grab had raised $4.8bn for its series H round as of mid-2019 but did not confirm a close for the round. Now however, the on-demand ride provider is set to raise approximately $714m from Mitsubishi UFJ Financial Group as part of a venture where the two will collaborate on a lending and insurance app, according to Nikkei. Amazon has been held up as a prime example of tech companies growing through diversification but it’s far from the only one.
SoftBank may be having difficulty luring external backers to its second Vision Fund but in the meantime it’s putting in its own money, $2.5bn since October according to Reuters sources, one of which said it is considering another $2.5bn while the fund carries on investing. Vision Fund is also reportedly lining up backers for a sub-$2bn hedge fund-like vehicle that will make public market investments.
Imara, a US-based developer of therapies for blood disorders, has filed to raise up to $86.3m in an initial public offering that would enable pharmaceutical firms Pfizer and Lundbeck to exit. Founded in 2016, Imara is working on drug treatments for haemoglobinopathies: disorders that affect the haemoglobin, the part of red blood cells that carry oxygen. It filed confidentially for the IPO in September 2019. It’s raised some $77m in series A and B funding, according to the filing – which is actually nearly $20m less than it had previously claimed, a discrepancy that’s rare for US companies (if a somewhat more common sight in China).
And the biggest deal on GUV was OMass Therapeutics, a UK-based drug design and development spinout of University of Oxford, which added £27.5m ($35.7m) of series A funding from investors including the university and its Oxford Sciences Innovation. Syncona led the extension with a $21.6m commitment – having also led the initial $17.9m close in 2018 with participation from OSI – to bring round’s total to $53.9m. OMass Therapeutics is working on therapies for immunological and genetic disorders.
Payment technology provider Toast has secured $400m in a series F round that bumped its valuation up from $2.7bn in April last year to $4.9bn. The round was co-led by TPG, Greenoaks Capital and existing investors Bessemer Venture Partners and Tiger Global, and it increased the company’s overall funding to more than $900m.
Endpoint protection platform developer SentinelOne has reportedly secured $200m at a $1.1bn valuation, with Insight Partners leading the round. Growth equity firm Insight also led SentinelOne’s last round, a $120m series E in June 2019 that included Samsung Venture Investment.
Yimi Dida is one of several trucking service providers contributing to China’s thriving logistics sector, and it has pulled in $143m in series D-plus funding from undisclosed investors, just over a year after it raised $266m in a Prologis-backed series D round.
Swiggy is continuing to battle Zomato for pole position in India’s online food delivery sector, and has received $113m in a series I round led by a reported $100m investment from Prosus Ventures, the unit formerly known as Naspers Ventures. You don’t see too many series I rounds, do you?
Unacademy is one of several companies operating in India’s thriving online education sector, and has grabbed $110m in a series E round that includes a relatively rare corporate venturing investment by Facebook.
Tier Mobility has extended its series B round to more than $100m, adding about $40m in debt and equity financing to the $60m it raised from investors including Axa Germany last October.
Elsewhere in Germany another transport-focused company has expanded its latest round, airborne taxi developer Volocopter increasing its series C to $94m with funding from investors including Deutsche Bahn’s logistics subsidiary, DB Schenke, as well as Mitsui Sumitomo Insurance and MS&AD Ventures.
Spruce Biosciences has nabbed $88m in a series B round that included Novo, one of two named investors in its $20m series A three years ago. The company is currently enrolling patients for a phase 2 trial for a treatment intended to reduce heavy steroid doses necessary to combat a genetic hormonal disorder known as congenital adrenal hyperplasia.
Intel Capital has led a $74m round for cybersecurity software provider ZeroFox, boosting its total funding to $162m. ZeroFox has also formed a collaboration agreement with an Intel ecosystem of software vendors known as Intel AI Builders covering artificial intelligence development.
Solar energy services provider Sunseap has raised $72m from energy utility Banpy as part of a series D round that is reportedly now sized at $146m. The round’s other participants include Temasek and ABC World Asia while Chow Tai Fook Enterprises and Shell Technology Ventures are among its existing backers.
China International Capital Corporation’s CICC Capital unit has accumulated more than $229m for a biomedicine fund that follows a $1bn healthcare investment vehicle formed with AstraZeneca late last year. Corporate backers Hebei Port, Pharscin Pharma, Xiamen Fig, Fujian Sunner and Sichuan Daily Press subsidiary Xinwen Venture Capital are all among the LPs in the latest fund.
Biopharmaceutical company Walvax Technology is deploying roughly $21m for a biomedicine fund with a targeted close of about $87m that will be managed by Jinsheng Capital. Walvax is relatively new to corporate venturing but there seems to be a fair bit of activity in China right now concerning healthcare investment funds.
Mobile content discovery platform Digital Turbine has agreed to purchase US-based peer Mobile Posse in a deal reported by DC Inno to be about $66m in size, allowing telecommunications group SoftBank to exit.
“Funky Chunk” Kevin MacLeod (incompetech.com)
Licensed under Creative Commons: By Attribution 3.0